Welcome to our dedicated page for Moderna news (Ticker: MRNA), a resource for investors and traders seeking the latest updates and insights on Moderna stock.
Moderna, Inc. reports developments in mRNA medicines, including commercial vaccines, investigational respiratory vaccines, oncology programs and rare-disease candidates. News commonly covers regulatory authorizations and agency interactions for products such as Spikevax, mRESVIA, mNEXSPIKE and mCOMBRIAX, as well as clinical data for seasonal influenza, pandemic influenza and cancer immunotherapy programs including intismeran autogene and mRNA-4359.
Company updates also include quarterly financial results, revenue mix, expense actions, strategic partnerships, scientific meeting presentations and intellectual-property matters tied to Moderna's infectious disease portfolio and broader mRNA technology platform.
Moderna, Inc. (NASDAQ: MRNA) will host a live conference call and webcast on November 4, 2021, at 8:00 a.m. ET to discuss its Q3 2021 financial results and provide a corporate update. Interested parties can participate by calling 866-922-5184 (domestic) or 409-937-8950 (international) with conference ID 9177025. A webcast will be available on the Moderna Investors website and archived for a year. Moderna has rapidly advanced its mRNA therapeutics, particularly in COVID-19 vaccines, showcasing significant growth in the biotech field.
Moderna announced a significant agreement with COVAX to supply an additional 176.5 million doses of its COVID-19 vaccine. The doses are priced at an average of less than $10 per 100 µg dose, aligning with Moderna's global access principles. Additionally, the company has requested regulatory authorization for a 50 µg booster dose, which could enhance supply for low-income countries. COVAX has already secured over 210 million doses, with options for further purchases. This partnership aims to promote equitable vaccine access worldwide.
Moderna (NASDAQ: MRNA) is set to invest up to $500 million in building a state-of-the-art mRNA manufacturing facility in Africa. This facility aims to produce up to 500 million vaccine doses annually. The investment reflects Moderna's commitment to expanding its global manufacturing capacity and enhancing its mRNA platform, which has been pivotal in COVID-19 vaccine production. The company plans to begin the site selection process soon. Moderna has delivered over 500 million doses of its COVID-19 vaccine globally to date.
Moderna (NASDAQ: MRNA) has launched the Moderna Fellowship Program aimed at fostering a new generation of leaders in mRNA therapeutics and vaccine research. The initiative will select approximately 50 global fellows in its first year, focusing on infectious diseases. Dr. Greg Poland, an expert in infectious diseases, will chair the program. This effort underscores Moderna's commitment to supporting independent research and advancing mRNA-based innovations to improve patient care and population health.
Moderna, Inc. (NASDAQ: MRNA) announced that the European Medicines Agency has authorized a third dose of its COVID-19 vaccine, Spikevax, for severely immunocompromised individuals aged 12 years and older, to be administered at least 28 days after the second dose. Recent studies indicate that a third dose may enhance immune response in this vulnerable population. Moderna reaffirms its commitment to combatting COVID-19 through its mRNA technology, which has yielded effective vaccines and therapeutics.
Moderna, Inc. (NASDAQ: MRNA) has announced plans to invest in a new 462,000 sq. ft. science center in Cambridge, Massachusetts, aiming for LEED Zero certification. This facility will support its mRNA therapeutics and vaccines, focusing on sustainability and collaboration. Construction has begun, with phased move-in expected in 2023. Alexandria Real Estate Equities (NYSE: ARE) is the development partner, while Jones Lang LaSalle (NYSE: JLL) facilitated the site selection. Moderna's pipeline includes 37 programs, 22 of which are in clinical studies.
Moderna (Nasdaq: MRNA) announced that President Stephen Hoge, M.D., will join a fireside chat at Chardan’s Virtual 5th Annual Genetic Medicines Conference on October 5 at 1:00 p.m. ET. Investors can access a live webcast of the event on Moderna's website under “Events and Presentations.” The discussion will be archived for 30 days post-event. Moderna has evolved significantly in its 10 years, focusing on mRNA therapeutics and vaccines, including COVID-19, and has built a diverse clinical portfolio alongside robust manufacturing capabilities.
Moderna (MRNA) announced a supply agreement with the government of Peru for 20 million doses of its COVID-19 vaccine, with delivery commencing in Q1 2022. The vaccine is not yet approved for use in Peru, and Moderna will seek regulatory approvals prior to distribution. Corinne Le Goff, Moderna's CCO, expressed appreciation for the agreement, emphasizing the company's commitment to address the pandemic globally. The press release includes forward-looking statements regarding regulatory processes and delivery timelines, noting associated risks and uncertainties.
Moderna, Inc. (NASDAQ: MRNA) announces that Health Canada has granted full approval for SPIKEVAX (elasomeran mRNA vaccine), previously known as COVID-19 Vaccine Moderna. This marks a significant milestone as it's the first complete approval for SPIKEVAX. The approval is based on Phase 3 COVE study results, showing 93% efficacy with sustained protection for six months post-second dose. SPIKEVAX is indicated for individuals aged 12 and older, expanding its earlier emergency use for adults and adolescents. The company expresses gratitude towards Health Canada and the Canadian Government for their collaboration.
Moderna (MRNA) announces that its COVID-19 vaccine, mRNA-1273, remains highly effective against the Delta variant. A study involving 352,878 vaccinated individuals indicated an effectiveness rate of 87% against COVID-19 diagnosis and 96% against hospitalization. An analysis of their Phase 3 COVE study revealed a 36% reduction in breakthrough infections for those vaccinated more recently compared to those vaccinated earlier. The company advocates for a booster dose to enhance immunity and will share findings in a conference call.